<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid/><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid">PMC11497668</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid-ver">PMC11497668.1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaid">11497668</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaiid">11497668</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">39132759</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1002/alz.13879</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">ALZ13879</article-id></all-ids><extracted-table><table-id>alz13879-tbl-0001</table-id><table-label>TABLE 1</table-label><table-caption>Participant characteristics in the Framingham Heart Study.</table-caption><table-wrap-foot>Abbreviations: BMI, body mass index; FLI, free leptin index; HVOT, Hooper Visual Organization Test.; IQR, interquartile range; MRI, magnetic resonance imaging; NP, neuropsychological evaluation; PSMD, peak width of skeletonized mean diffusivity; SD, standard deviation; sOB‐R, soluble leptin receptor; TMT, Trail Making Test; WHR, waist‐to‐hip ratio; WMH, white matter hyperintensity.aPrevalent cardiovascular disease includes history of transient ischemic attack, coronary heart disease, congestive heart failure, or peripheral vascular disease.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="alz13879-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Participant characteristics in the Framingham Heart Study.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Demographic, anthropometric, and clinical characteristics</th><th align="left" rowspan="1" colspan="1">NP sample (<italic toggle="yes">n</italic> = 2262)</th><th align="left" rowspan="1" colspan="1">MRI sample (<italic toggle="yes">n</italic> = 2028)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Women</td><td align="char" rowspan="1" colspan="1">1186 (52.4)</td><td align="char" rowspan="1" colspan="1">1070 (52.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Men</td><td align="char" rowspan="1" colspan="1">1076 (47.6)</td><td align="char" rowspan="1" colspan="1">958 (47.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years, mean (SD)</td><td align="char" rowspan="1" colspan="1">40.4 (8.6)</td><td align="char" rowspan="1" colspan="1">40.2 (8.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Race, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Black</td><td align="char" rowspan="1" colspan="1">3 (0.1)</td><td align="char" rowspan="1" colspan="1">3 (0.1)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">White</td><td align="char" rowspan="1" colspan="1">2251 (99.5)</td><td align="char" rowspan="1" colspan="1">2018 (99.5)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Other</td><td align="char" rowspan="1" colspan="1">8 (0.4)</td><td align="char" rowspan="1" colspan="1">7 (0.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ethnicity</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hispanic</td><td align="char" rowspan="1" colspan="1">2 (0.1)</td><td align="char" rowspan="1" colspan="1">2 (0.1)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Non‐Hispanic</td><td align="char" rowspan="1" colspan="1">2260 (99.9)</td><td align="char" rowspan="1" colspan="1">2026 (99.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Education <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Bachelor's degree</td><td align="char" rowspan="1" colspan="1">843 (37.3)</td><td align="char" rowspan="1" colspan="1">767 (37.9)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Graduate degree</td><td align="char" rowspan="1" colspan="1">380 (16.8)</td><td align="char" rowspan="1" colspan="1">347 (17.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Highschool or less</td><td align="char" rowspan="1" colspan="1">310 (13.7)</td><td align="char" rowspan="1" colspan="1">268 (13.3)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Some college</td><td align="char" rowspan="1" colspan="1">729 (32.2)</td><td align="char" rowspan="1" colspan="1">640 (31.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood draw to NP or MRI interval, years, mean (SD)</td><td align="char" rowspan="1" colspan="1">7.8 (1.1)</td><td align="char" rowspan="1" colspan="1">7.8 (1.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">26.9 (5.4)</td><td align="char" rowspan="1" colspan="1">26.7 (5.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">WHR, mean (SD)</td><td align="char" rowspan="1" colspan="1">0.92 (0.08)</td><td align="char" rowspan="1" colspan="1">0.92 (0.08)</td></tr><tr><td align="left" rowspan="1" colspan="1">Excess WHR, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">No</td><td align="char" rowspan="1" colspan="1">1705 (75.5)</td><td align="char" rowspan="1" colspan="1">1543 (76.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="char" rowspan="1" colspan="1">553 (24.5)</td><td align="char" rowspan="1" colspan="1">483 (23.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure, mmHg, mean (SD)</td><td align="char" rowspan="1" colspan="1">116.9 (13.9)</td><td align="char" rowspan="1" colspan="1">116.7 (13.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Antihypertensive medication use, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">174 (7.7)</td><td align="char" rowspan="1" colspan="1">156 (7.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">58 (2.6)</td><td align="char" rowspan="1" colspan="1">50 (2.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoking, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">299 (13.2)</td><td align="char" rowspan="1" colspan="1">257 (12.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalent cardiovascular disease <xref rid="alz13879-tbl1-note-0001" ref-type="table-fn"><sup>a</sup></xref>, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">20 (0.9)</td><td align="char" rowspan="1" colspan="1">14 (0.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Leptin markers</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Leptin, ng/mL, median (IQR)</td><td align="char" rowspan="1" colspan="1">7280 (3645, 14,973)</td><td align="char" rowspan="1" colspan="1">7330 (3623, 14,861)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">sOB‐R, ng/mL, median (IQR)</td><td align="char" rowspan="1" colspan="1">17.7 (12.1, 23.7)</td><td align="char" rowspan="1" colspan="1">18.2 (12.3, 24.1)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">FLI, median (IQR)</td><td align="char" rowspan="1" colspan="1">423.0 (193.5, 970.1)</td><td align="char" rowspan="1" colspan="1">418.3 (188.4, 961.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Neuropsychological test scores</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Similarities, mean (SD)</td><td align="char" rowspan="1" colspan="1">17.34 (3.06)</td><td align="char" rowspan="1" colspan="1">17.36 (3.09)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">TMT part A, min, median (IQR)</td><td align="char" rowspan="1" colspan="1">0.40 (0.32, 0.48)</td><td align="char" rowspan="1" colspan="1">0.38 (0.32, 0.47)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">TMT part B, min, median (IQR)</td><td align="char" rowspan="1" colspan="1">0.93 (0.75, 1.18)</td><td align="char" rowspan="1" colspan="1">0.93 (0.75, 1.17)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Logical memory delayed recall, mean (SD)</td><td align="char" rowspan="1" colspan="1">11.79 (3.58)</td><td align="char" rowspan="1" colspan="1">11.79 (3.59)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">HVOT, median (IQR)</td><td align="char" rowspan="1" colspan="1">27.0 (25.5, 28.0)</td><td align="char" rowspan="1" colspan="1">27.0 (25.5, 28.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">MRI measures (<italic toggle="yes">n</italic> = 2129)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Total cranial volume, cm<sup>3</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">1264.1 (125.3)</td><td align="char" rowspan="1" colspan="1">1263.1 (125.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Total brain volume, cm<sup>3</sup>, mean (SD)1</td><td align="char" rowspan="1" colspan="1">998.4 (102.6)</td><td align="char" rowspan="1" colspan="1">997.9 (102.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cortical gray matter volume, cm<sup>3</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">480.2 (46.6)</td><td align="char" rowspan="1" colspan="1">480.0 (46.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hippocampal volume, cm<sup>3</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">6.86 (0.72)</td><td align="char" rowspan="1" colspan="1">6.86 (0.72)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">WMH volume, cm<sup>3</sup>, median (IQR)</td><td align="char" rowspan="1" colspan="1">0.42 (0.21, 0.88)</td><td align="char" rowspan="1" colspan="1">0.42 (0.21, 0.86)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Fractional anisotropy, mean (SD)</td><td align="char" rowspan="1" colspan="1">0.62 (0.01)</td><td align="char" rowspan="1" colspan="1">0.63 (0.01)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Free water, median (IQR)</td><td align="char" rowspan="1" colspan="1">0.20 (0.19, 0.21)</td><td align="char" rowspan="1" colspan="1">0.20 (0.19, 0.21)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">PSMD × 10<sup>−4</sup>, median (IQR)</td><td align="char" rowspan="1" colspan="1">2.16 (2.01, 2.36)</td><td align="char" rowspan="1" colspan="1">2.16 (2.01, 2.36)</td></tr></tbody></table><table-wrap-foot><fn id="alz13879-tbl1-note-0002"><p>Abbreviations: BMI, body mass index; FLI, free leptin index; HVOT, Hooper Visual Organization Test.; IQR, interquartile range; MRI, magnetic resonance imaging; NP, neuropsychological evaluation; PSMD, peak width of skeletonized mean diffusivity; SD, standard deviation; sOB‐R, soluble leptin receptor; TMT, Trail Making Test; WHR, waist‐to‐hip ratio; WMH, white matter hyperintensity.</p></fn><fn id="alz13879-tbl1-note-0001"><label><sup>a</sup></label><p>Prevalent cardiovascular disease includes history of transient ischemic attack, coronary heart disease, congestive heart failure, or peripheral vascular disease.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></original-table><transformed-table>TABLE 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Participant characteristics in the Framingham Heart Study.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col align="left"/><col align="char" char="("/><col align="char" char="("/><thead><tr style="border-bottom:solid 1px #000000"><th align="left">Demographic, anthropometric, and clinical characteristics</th><th align="left">NP sample (n = 2262)</th><th align="left">MRI sample (n = 2028)</th></tr></thead><tbody><tr><td align="left">Sex, n (%)</td><td align="char"/><td align="char"/></tr><tr><td style="padding-left:10%" align="left">Women</td><td align="char">1186 (52.4)</td><td align="char">1070 (52.8)</td></tr><tr><td style="padding-left:10%" align="left">Men</td><td align="char">1076 (47.6)</td><td align="char">958 (47.2)</td></tr><tr><td align="left">Age, years, mean (SD)</td><td align="char">40.4 (8.6)</td><td align="char">40.2 (8.7)</td></tr><tr><td align="left">Race, n (%)</td><td align="char"/><td align="char"/></tr><tr><td style="padding-left:10%" align="left">Black</td><td align="char">3 (0.1)</td><td align="char">3 (0.1)</td></tr><tr><td style="padding-left:10%" align="left">White</td><td align="char">2251 (99.5)</td><td align="char">2018 (99.5)</td></tr><tr><td style="padding-left:10%" align="left">Other</td><td align="char">8 (0.4)</td><td align="char">7 (0.4)</td></tr><tr><td align="left">Ethnicity</td><td align="char"/><td align="char"/></tr><tr><td style="padding-left:10%" align="left">Hispanic</td><td align="char">2 (0.1)</td><td align="char">2 (0.1)</td></tr><tr><td style="padding-left:10%" align="left">Non‐Hispanic</td><td align="char">2260 (99.9)</td><td align="char">2026 (99.9)</td></tr><tr><td align="left">Education n (%)</td><td align="char"/><td align="char"/></tr><tr><td style="padding-left:10%" align="left">Bachelor's degree</td><td align="char">843 (37.3)</td><td align="char">767 (37.9)</td></tr><tr><td style="padding-left:10%" align="left">Graduate degree</td><td align="char">380 (16.8)</td><td align="char">347 (17.2)</td></tr><tr><td style="padding-left:10%" align="left">Highschool or less</td><td align="char">310 (13.7)</td><td align="char">268 (13.3)</td></tr><tr><td style="padding-left:10%" align="left">Some college</td><td align="char">729 (32.2)</td><td align="char">640 (31.7)</td></tr><tr><td align="left">Blood draw to NP or MRI interval, years, mean (SD)</td><td align="char">7.8 (1.1)</td><td align="char">7.8 (1.0)</td></tr><tr><td align="left">BMI, kg/m2, mean (SD)</td><td align="char">26.9 (5.4)</td><td align="char">26.7 (5.2)</td></tr><tr><td align="left">WHR, mean (SD)</td><td align="char">0.92 (0.08)</td><td align="char">0.92 (0.08)</td></tr><tr><td align="left">Excess WHR, n (%)</td><td align="char"/><td align="char"/></tr><tr><td style="padding-left:10%" align="left">No</td><td align="char">1705 (75.5)</td><td align="char">1543 (76.2)</td></tr><tr><td style="padding-left:10%" align="left">Yes</td><td align="char">553 (24.5)</td><td align="char">483 (23.8)</td></tr><tr><td align="left">Systolic blood pressure, mmHg, mean (SD)</td><td align="char">116.9 (13.9)</td><td align="char">116.7 (13.9)</td></tr><tr><td align="left">Antihypertensive medication use, n (%)</td><td align="char">174 (7.7)</td><td align="char">156 (7.7)</td></tr><tr><td align="left">Diabetes mellitus, n (%)</td><td align="char">58 (2.6)</td><td align="char">50 (2.5)</td></tr><tr><td align="left">Current smoking, n (%)</td><td align="char">299 (13.2)</td><td align="char">257 (12.7)</td></tr><tr><td align="left">Prevalent cardiovascular disease ???, n (%)</td><td align="char">20 (0.9)</td><td align="char">14 (0.7)</td></tr><tr><td align="left">Leptin markers</td><td align="char"/><td align="char"/></tr><tr><td style="padding-left:10%" align="left">Leptin, ng/mL, median (IQR)</td><td align="char">7280 (3645, 14,973)</td><td align="char">7330 (3623, 14,861)</td></tr><tr><td style="padding-left:10%" align="left">sOB‐R, ng/mL, median (IQR)</td><td align="char">17.7 (12.1, 23.7)</td><td align="char">18.2 (12.3, 24.1)</td></tr><tr><td style="padding-left:10%" align="left">FLI, median (IQR)</td><td align="char">423.0 (193.5, 970.1)</td><td align="char">418.3 (188.4, 961.7)</td></tr><tr><td align="left">Neuropsychological test scores</td><td align="char"/><td align="char"/></tr><tr><td style="padding-left:10%" align="left">Similarities, mean (SD)</td><td align="char">17.34 (3.06)</td><td align="char">17.36 (3.09)</td></tr><tr><td style="padding-left:10%" align="left">TMT part A, min, median (IQR)</td><td align="char">0.40 (0.32, 0.48)</td><td align="char">0.38 (0.32, 0.47)</td></tr><tr><td style="padding-left:10%" align="left">TMT part B, min, median (IQR)</td><td align="char">0.93 (0.75, 1.18)</td><td align="char">0.93 (0.75, 1.17)</td></tr><tr><td style="padding-left:10%" align="left">Logical memory delayed recall, mean (SD)</td><td align="char">11.79 (3.58)</td><td align="char">11.79 (3.59)</td></tr><tr><td style="padding-left:10%" align="left">HVOT, median (IQR)</td><td align="char">27.0 (25.5, 28.0)</td><td align="char">27.0 (25.5, 28.0)</td></tr><tr><td align="left">MRI measures (n = 2129)</td><td align="char"/><td align="char"/></tr><tr><td style="padding-left:10%" align="left">Total cranial volume, cm3, mean (SD)</td><td align="char">1264.1 (125.3)</td><td align="char">1263.1 (125.8)</td></tr><tr><td style="padding-left:10%" align="left">Total brain volume, cm3, mean (SD)1</td><td align="char">998.4 (102.6)</td><td align="char">997.9 (102.8)</td></tr><tr><td style="padding-left:10%" align="left">Cortical gray matter volume, cm3, mean (SD)</td><td align="char">480.2 (46.6)</td><td align="char">480.0 (46.7)</td></tr><tr><td style="padding-left:10%" align="left">Hippocampal volume, cm3, mean (SD)</td><td align="char">6.86 (0.72)</td><td align="char">6.86 (0.72)</td></tr><tr><td style="padding-left:10%" align="left">WMH volume, cm3, median (IQR)</td><td align="char">0.42 (0.21, 0.88)</td><td align="char">0.42 (0.21, 0.86)</td></tr><tr><td style="padding-left:10%" align="left">Fractional anisotropy, mean (SD)</td><td align="char">0.62 (0.01)</td><td align="char">0.63 (0.01)</td></tr><tr><td style="padding-left:10%" align="left">Free water, median (IQR)</td><td align="char">0.20 (0.19, 0.21)</td><td align="char">0.20 (0.19, 0.21)</td></tr><tr><td style="padding-left:10%" align="left">PSMD × 10−4, median (IQR)</td><td align="char">2.16 (2.01, 2.36)</td><td align="char">2.16 (2.01, 2.36)</td></tr></tbody></table></div>Abbreviations: BMI, body mass index; FLI, free leptin index; HVOT, Hooper Visual Organization Test.; IQR, interquartile range; MRI, magnetic resonance imaging; NP, neuropsychological evaluation; PSMD, peak width of skeletonized mean diffusivity; SD, standard deviation; sOB‐R, soluble leptin receptor; TMT, Trail Making Test; WHR, waist‐to‐hip ratio; WMH, white matter hyperintensity.aPrevalent cardiovascular disease includes history of transient ischemic attack, coronary heart disease, congestive heart failure, or peripheral vascular disease.John Wiley &amp; Sons, Ltd.</transformed-table></extracted-table><extracted-table><table-id>alz13879-tbl-0002</table-id><table-label>TABLE 2</table-label><table-caption>Associations of leptin markers with neuropsychological test scores (n = 2262).</table-caption><table-wrap-foot>Note: Results from linear regression models with the respective neuropsychological test score as the outcome and the respective leptin marker as the main predictor. Models are adjusted for age, sex, education, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and neuropsychological assessment. Values represent beta coefficients (β), and their corresponding standard errors (SE) and raw p‐values (p). Statistically significant findings after false discovery rate control at 5% using the Benjamini‐Hochberg procedure are indicated in bold.Abbreviations: FLI, free leptin index; HVOT, Hooper Visual Organization Test.;sOB‐R, soluble leptin receptor; TMT, Trail Making Test.aThese variables have been natural log‐transformed to normalize their distributions.bScores were multiplied by −1 so that higher scores reflect better cognitive performance.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="alz13879-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Associations of leptin markers with neuropsychological test scores (<italic toggle="yes">n</italic> = 2262).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Leptin<xref rid="alz13879-tbl2-note-0002" ref-type="table-fn"><sup>a</sup></xref></th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">sOB‐R<xref rid="alz13879-tbl2-note-0002" ref-type="table-fn"><sup>a</sup></xref></th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">FLI<xref rid="alz13879-tbl2-note-0002" ref-type="table-fn"><sup>a</sup></xref></th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Cognitive outcome</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">β</italic></th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">β</italic></th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">β</italic></th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Similarities</td><td align="char" rowspan="1" colspan="1">0.004</td><td align="left" rowspan="1" colspan="1">0.031</td><td align="left" rowspan="1" colspan="1">0.90</td><td align="char" rowspan="1" colspan="1">−0.001</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="char" rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">0.029</td><td align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">TMT part A<xref rid="alz13879-tbl2-note-0002" ref-type="table-fn"><sup>a</sup></xref>, <xref rid="alz13879-tbl2-note-0003" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" rowspan="1" colspan="1">−0.057</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="char" rowspan="1" colspan="1">0.036</td><td align="left" rowspan="1" colspan="1">0.021</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="char" rowspan="1" colspan="1">−0.068</td><td align="left" rowspan="1" colspan="1">0.028</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">TMT part B<xref rid="alz13879-tbl2-note-0002" ref-type="table-fn"><sup>a</sup></xref>, <xref rid="alz13879-tbl2-note-0003" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" rowspan="1" colspan="1">0.026</td><td align="left" rowspan="1" colspan="1">0.031</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="char" rowspan="1" colspan="1">−0.018</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1">0.40</td><td align="char" rowspan="1" colspan="1">0.032</td><td align="left" rowspan="1" colspan="1">0.029</td><td align="left" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Logical memory delayed recall</td><td align="char" rowspan="1" colspan="1">0.057</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="char" rowspan="1" colspan="1">−0.029</td><td align="left" rowspan="1" colspan="1">0.021</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="char" rowspan="1" colspan="1">0.062</td><td align="left" rowspan="1" colspan="1">0.028</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">HVOT<xref rid="alz13879-tbl2-note-0002" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" rowspan="1" colspan="1">0.032</td><td align="left" rowspan="1" colspan="1">0.031</td><td align="left" rowspan="1" colspan="1">0.30</td><td align="char" rowspan="1" colspan="1">−0.011</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1">0.62</td><td align="char" rowspan="1" colspan="1">0.031</td><td align="left" rowspan="1" colspan="1">0.029</td><td align="left" rowspan="1" colspan="1">0.29</td></tr></tbody></table><table-wrap-foot><fn id="alz13879-tbl2-note-0001"><p><italic toggle="yes">Note</italic>: Results from linear regression models with the respective neuropsychological test score as the outcome and the respective leptin marker as the main predictor. Models are adjusted for age, sex, education, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and neuropsychological assessment. Values represent beta coefficients (<italic toggle="yes">β</italic>), and their corresponding standard errors (SE) and raw <italic toggle="yes">p</italic>‐values (<italic toggle="yes">p</italic>). Statistically significant findings after false discovery rate control at 5% using the Benjamini‐Hochberg procedure are indicated in bold.</p></fn><fn id="alz13879-tbl2-note-0004"><p>Abbreviations: FLI, free leptin index; HVOT, Hooper Visual Organization Test.;sOB‐R, soluble leptin receptor; TMT, Trail Making Test.</p></fn><fn id="alz13879-tbl2-note-0002"><label><sup>a</sup></label><p>These variables have been natural log‐transformed to normalize their distributions.</p></fn><fn id="alz13879-tbl2-note-0003"><label><sup>b</sup></label><p>Scores were multiplied by −1 so that higher scores reflect better cognitive performance.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></original-table><transformed-table>TABLE 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Associations of leptin markers with neuropsychological test scores (n = 2262).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col align="left"/><col align="char" char="."/><col align="left"/><col align="left"/><col align="char" char="."/><col align="left"/><col align="left"/><col align="char" char="."/><col align="left"/><col align="left"/><thead><tr><th align="left"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left">Leptin???</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left">sOB‐R???</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left">FLI???</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left">Cognitive outcome</th><th align="left">β</th><th align="left">SE</th><th align="left">p‐value</th><th align="left">β</th><th align="left">SE</th><th align="left">p‐value</th><th align="left">β</th><th align="left">SE</th><th align="left">p‐value</th></tr></thead><tbody><tr><td align="left">Similarities</td><td align="char">0.004</td><td align="left">0.031</td><td align="left">0.90</td><td align="char">−0.001</td><td align="left">0.022</td><td align="left">0.95</td><td align="char">0.003</td><td align="left">0.029</td><td align="left">0.92</td></tr><tr><td align="left">TMT part A???, ???</td><td align="char">−0.057</td><td align="left">0.030</td><td align="left">0.06</td><td align="char">0.036</td><td align="left">0.021</td><td align="left">0.09</td><td align="char">−0.068</td><td align="left">0.028</td><td align="left">0.02</td></tr><tr><td align="left">TMT part B???, ???</td><td align="char">0.026</td><td align="left">0.031</td><td align="left">0.39</td><td align="char">−0.018</td><td align="left">0.022</td><td align="left">0.40</td><td align="char">0.032</td><td align="left">0.029</td><td align="left">0.26</td></tr><tr><td align="left">Logical memory delayed recall</td><td align="char">0.057</td><td align="left">0.030</td><td align="left">0.06</td><td align="char">−0.029</td><td align="left">0.021</td><td align="left">0.18</td><td align="char">0.062</td><td align="left">0.028</td><td align="left">0.03</td></tr><tr><td align="left">HVOT???</td><td align="char">0.032</td><td align="left">0.031</td><td align="left">0.30</td><td align="char">−0.011</td><td align="left">0.022</td><td align="left">0.62</td><td align="char">0.031</td><td align="left">0.029</td><td align="left">0.29</td></tr></tbody></table></div>Note: Results from linear regression models with the respective neuropsychological test score as the outcome and the respective leptin marker as the main predictor. Models are adjusted for age, sex, education, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and neuropsychological assessment. Values represent beta coefficients (β), and their corresponding standard errors (SE) and raw p‐values (p). Statistically significant findings after false discovery rate control at 5% using the Benjamini‐Hochberg procedure are indicated in bold.Abbreviations: FLI, free leptin index; HVOT, Hooper Visual Organization Test.;sOB‐R, soluble leptin receptor; TMT, Trail Making Test.aThese variables have been natural log‐transformed to normalize their distributions.bScores were multiplied by −1 so that higher scores reflect better cognitive performance.John Wiley &amp; Sons, Ltd.</transformed-table></extracted-table><extracted-table><table-id>alz13879-tbl-0003</table-id><table-label>TABLE 3</table-label><table-caption>Associations of leptin markers with MRI markers of brain atrophy and vascular injury (n = 2028).</table-caption><table-wrap-foot>Note: Results from linear regression models with the respective MRI marker as the outcome and the respective leptin marker as the main predictor. Models are adjusted for age, sex, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and MRI acquisition. Values represent beta coefficients (β), and their corresponding standard errors (SE) and raw p values (p). Statistically significant findings after false discovery rate control at 5% using the Benjamini‐Hochberg procedure are indicated in bold.Abbreviations: FLI, free leptin index, MRI, magnetic resonance imaging; PSMD, peak width of skeletonized mean diffusivity.; sOB‐R, soluble leptin receptor; WMH, white matter hyperintensity.aThese variables have been natural log‐transformed to normalize their distributions.bas percentage of total cranial volume.cModels are further adjusted for total cranial volume.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="alz13879-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Associations of leptin markers with MRI markers of brain atrophy and vascular injury (<italic toggle="yes">n</italic> = 2028).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Leptin<xref rid="alz13879-tbl3-note-0002" ref-type="table-fn"><sup>a</sup></xref></th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">sOB‐R<xref rid="alz13879-tbl3-note-0002" ref-type="table-fn"><sup>a</sup></xref></th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">FLI<xref rid="alz13879-tbl3-note-0002" ref-type="table-fn"><sup>a</sup></xref></th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">MRI outcome</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">β</italic></th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">β</italic></th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th><th align="left" rowspan="1" colspan="1">β</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total brain volume<xref rid="alz13879-tbl3-note-0003" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" rowspan="1" colspan="1">0.008</td><td align="char" rowspan="1" colspan="1">0.029</td><td align="char" rowspan="1" colspan="1">0.78</td><td align="char" rowspan="1" colspan="1">−0.013</td><td align="char" rowspan="1" colspan="1">0.020</td><td align="char" rowspan="1" colspan="1">0.52</td><td align="char" rowspan="1" colspan="1">0.016</td><td align="char" rowspan="1" colspan="1">0.027</td><td align="char" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Cortical gray matter volume<xref rid="alz13879-tbl3-note-0003" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" rowspan="1" colspan="1">0.023</td><td align="char" rowspan="1" colspan="1">0.028</td><td align="char" rowspan="1" colspan="1">0.41</td><td align="char" rowspan="1" colspan="1">−0.009</td><td align="char" rowspan="1" colspan="1">0.020</td><td align="char" rowspan="1" colspan="1">0.66</td><td align="char" rowspan="1" colspan="1">0.022</td><td align="char" rowspan="1" colspan="1">0.026</td><td align="char" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Hippocampal volume<xref rid="alz13879-tbl3-note-0003" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" rowspan="1" colspan="1">0.011</td><td align="char" rowspan="1" colspan="1">0.033</td><td align="char" rowspan="1" colspan="1">0.73</td><td align="char" rowspan="1" colspan="1">−0.012</td><td align="char" rowspan="1" colspan="1">0.024</td><td align="char" rowspan="1" colspan="1">0.62</td><td align="char" rowspan="1" colspan="1">0.017</td><td align="char" rowspan="1" colspan="1">0.031</td><td align="char" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">WMH volume<xref rid="alz13879-tbl3-note-0002" ref-type="table-fn"><sup>a</sup></xref>, <xref rid="alz13879-tbl3-note-0003" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" rowspan="1" colspan="1">−0.034</td><td align="char" rowspan="1" colspan="1">0.029</td><td align="char" rowspan="1" colspan="1">0.24</td><td align="char" rowspan="1" colspan="1">0.040</td><td align="char" rowspan="1" colspan="1">0.021</td><td align="char" rowspan="1" colspan="1">0.05</td><td align="char" rowspan="1" colspan="1">−0.054</td><td align="char" rowspan="1" colspan="1">0.027</td><td align="char" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Fractional anisotropy<xref rid="alz13879-tbl3-note-0004" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" rowspan="1" colspan="1">0.041</td><td align="char" rowspan="1" colspan="1">0.029</td><td align="char" rowspan="1" colspan="1">0.16</td><td align="char" rowspan="1" colspan="1"><bold>−0.114</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.020</bold></td><td align="char" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.115</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.027</bold></td><td align="char" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Free water<xref rid="alz13879-tbl3-note-0002" ref-type="table-fn"><sup>a</sup></xref>, <xref rid="alz13879-tbl3-note-0004" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" rowspan="1" colspan="1">−0.039</td><td align="char" rowspan="1" colspan="1">0.031</td><td align="char" rowspan="1" colspan="1">0.21</td><td align="char" rowspan="1" colspan="1"><bold>0.091</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.022</bold></td><td align="char" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="char" rowspan="1" colspan="1"><bold>−0.096</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.029</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">PSMD<xref rid="alz13879-tbl3-note-0002" ref-type="table-fn"><sup>a</sup></xref>, <xref rid="alz13879-tbl3-note-0004" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" rowspan="1" colspan="1">−0.038</td><td align="char" rowspan="1" colspan="1">0.029</td><td align="char" rowspan="1" colspan="1">0.20</td><td align="char" rowspan="1" colspan="1"><bold>0.078</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.021</bold></td><td align="char" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="char" rowspan="1" colspan="1"><bold>−0.085</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.028</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.002</bold></td></tr></tbody></table><table-wrap-foot><fn id="alz13879-tbl3-note-0001"><p><italic toggle="yes">Note</italic>: Results from linear regression models with the respective MRI marker as the outcome and the respective leptin marker as the main predictor. Models are adjusted for age, sex, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and MRI acquisition. Values represent beta coefficients (<italic toggle="yes">β</italic>), and their corresponding standard errors (SE) and raw <italic toggle="yes">p</italic> values (<italic toggle="yes">p</italic>). Statistically significant findings after false discovery rate control at 5% using the Benjamini‐Hochberg procedure are indicated in bold.</p></fn><fn id="alz13879-tbl3-note-0005"><p>Abbreviations: FLI, free leptin index, MRI, magnetic resonance imaging; PSMD, peak width of skeletonized mean diffusivity.; sOB‐R, soluble leptin receptor; WMH, white matter hyperintensity.</p></fn><fn id="alz13879-tbl3-note-0002"><label><sup>a</sup></label><p>These variables have been natural log‐transformed to normalize their distributions.</p></fn><fn id="alz13879-tbl3-note-0003"><label><sup>b</sup></label><p>as percentage of total cranial volume.</p></fn><fn id="alz13879-tbl3-note-0004"><label><sup>c</sup></label><p>Models are further adjusted for total cranial volume.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></original-table><transformed-table>TABLE 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Associations of leptin markers with MRI markers of brain atrophy and vascular injury (n = 2028).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><thead><tr><th align="left"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left">Leptin???</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left">sOB‐R???</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left">FLI???</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left">MRI outcome</th><th align="left">β</th><th align="left">SE</th><th align="left">p‐value</th><th align="left">β</th><th align="left">SE</th><th align="left">p‐value</th><th align="left">β</th><th align="left">SE</th><th align="left">p‐value</th></tr></thead><tbody><tr><td align="left">Total brain volume???</td><td align="char">0.008</td><td align="char">0.029</td><td align="char">0.78</td><td align="char">−0.013</td><td align="char">0.020</td><td align="char">0.52</td><td align="char">0.016</td><td align="char">0.027</td><td align="char">0.56</td></tr><tr><td align="left">Cortical gray matter volume???</td><td align="char">0.023</td><td align="char">0.028</td><td align="char">0.41</td><td align="char">−0.009</td><td align="char">0.020</td><td align="char">0.66</td><td align="char">0.022</td><td align="char">0.026</td><td align="char">0.40</td></tr><tr><td align="left">Hippocampal volume???</td><td align="char">0.011</td><td align="char">0.033</td><td align="char">0.73</td><td align="char">−0.012</td><td align="char">0.024</td><td align="char">0.62</td><td align="char">0.017</td><td align="char">0.031</td><td align="char">0.58</td></tr><tr><td align="left">WMH volume???, ???</td><td align="char">−0.034</td><td align="char">0.029</td><td align="char">0.24</td><td align="char">0.040</td><td align="char">0.021</td><td align="char">0.05</td><td align="char">−0.054</td><td align="char">0.027</td><td align="char">0.05</td></tr><tr><td align="left">Fractional anisotropy???</td><td align="char">0.041</td><td align="char">0.029</td><td align="char">0.16</td><td align="char">−0.114</td><td align="char">0.020</td><td align="char">&lt;0.001</td><td align="char">0.115</td><td align="char">0.027</td><td align="char">&lt;0.001</td></tr><tr><td align="left">Free water???, ???</td><td align="char">−0.039</td><td align="char">0.031</td><td align="char">0.21</td><td align="char">0.091</td><td align="char">0.022</td><td align="char">&lt;0.001</td><td align="char">−0.096</td><td align="char">0.029</td><td align="char">0.001</td></tr><tr><td align="left">PSMD???, ???</td><td align="char">−0.038</td><td align="char">0.029</td><td align="char">0.20</td><td align="char">0.078</td><td align="char">0.021</td><td align="char">&lt;0.001</td><td align="char">−0.085</td><td align="char">0.028</td><td align="char">0.002</td></tr></tbody></table></div>Note: Results from linear regression models with the respective MRI marker as the outcome and the respective leptin marker as the main predictor. Models are adjusted for age, sex, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and MRI acquisition. Values represent beta coefficients (β), and their corresponding standard errors (SE) and raw p values (p). Statistically significant findings after false discovery rate control at 5% using the Benjamini‐Hochberg procedure are indicated in bold.Abbreviations: FLI, free leptin index, MRI, magnetic resonance imaging; PSMD, peak width of skeletonized mean diffusivity.; sOB‐R, soluble leptin receptor; WMH, white matter hyperintensity.aThese variables have been natural log‐transformed to normalize their distributions.bas percentage of total cranial volume.cModels are further adjusted for total cranial volume.John Wiley &amp; Sons, Ltd.</transformed-table></extracted-table><extracted-table><table-id>alz13879-tbl-0004</table-id><table-label>TABLE 4</table-label><table-caption>Participant characteristics in the MarkVCID‐1 sample (n = 89).</table-caption><table-wrap-foot>Abbreviations: BMI, body mass index; IQR, interquartile range; MRI, magnetic resonance imaging; NPX, Normalized Protein eXpression; PSMD, peak width of skeletonized mean diffusivity; SD, standard deviation; TMT, Trail Making Test.; WMH, white matter hyperintensity.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="alz13879-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Participant characteristics in the MarkVCID‐1 sample (<italic toggle="yes">n</italic> = 89).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Demographic, anthropometric, and clinical characteristics</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Women</td><td align="char" rowspan="1" colspan="1">66 (74.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Men</td><td align="char" rowspan="1" colspan="1">23 (25.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years, mean (SD)</td><td align="char" rowspan="1" colspan="1">70.5 (7.3)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Education, years, mean (SD)</td><td align="char" rowspan="1" colspan="1">14.3 (2.4)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">30.3 (6.4)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Systolic blood pressure, mmHg, mean (SD)</td><td align="char" rowspan="1" colspan="1">134.2 (17.9)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Antihypertensive medication use, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">46 (51.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Diabetes mellitus, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">24 (27.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Current smoking, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">22 (24.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Leptin markers</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Leptin, NPX, mean (SD)</td><td align="char" rowspan="1" colspan="1">−0.2 (1.4)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Leptin receptor, NPX, mean (SD)</td><td align="char" rowspan="1" colspan="1">0.1 (0.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Neuropsychological test scores</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">TMT part A, min, median (IQR)</td><td align="char" rowspan="1" colspan="1">0.57 (0.43, 0.70)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">TMT part B, min, median (IQR)</td><td align="char" rowspan="1" colspan="1">1.49 (1.21, 2.29)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Craft Story 21 Recall (Delayed), mean (SD)</td><td align="char" rowspan="1" colspan="1">17.2 (6.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">MRI measures</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Total cranial volume, cm<sup>3</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">1349.8 (142.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Total brain volume, cm<sup>3</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">1049.2 (109.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Total gray matter volume, cm<sup>3</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">582.8 (54.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">WMH volume, cm<sup>3</sup>, median (IQR)</td><td align="char" rowspan="1" colspan="1">1.91 (0.87, 3.22)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Fractional anisotropy, mean (SD)</td><td align="char" rowspan="1" colspan="1">0.50 (0.01)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Free water, median (IQR)</td><td align="char" rowspan="1" colspan="1">0.18 (0.17, 0.21)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">PSMD × 10<sup>−4</sup>, median (IQR)</td><td align="char" rowspan="1" colspan="1">3.25 (2.94, 3.49)</td></tr></tbody></table><table-wrap-foot><fn id="alz13879-tbl4-note-0001"><p>Abbreviations: BMI, body mass index; IQR, interquartile range; MRI, magnetic resonance imaging; NPX, Normalized Protein eXpression; PSMD, peak width of skeletonized mean diffusivity; SD, standard deviation; TMT, Trail Making Test.; WMH, white matter hyperintensity.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></original-table><transformed-table>TABLE 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Participant characteristics in the MarkVCID‐1 sample (n = 89).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col align="left"/><col align="char" char="("/><thead><tr style="border-bottom:solid 1px #000000"><th align="left">Demographic, anthropometric, and clinical characteristics</th><th align="left">n (%)</th></tr></thead><tbody><tr><td align="left">Sex</td><td align="char"/></tr><tr><td style="padding-left:10%" align="left">Women</td><td align="char">66 (74.2)</td></tr><tr><td style="padding-left:10%" align="left">Men</td><td align="char">23 (25.8)</td></tr><tr><td align="left">Age, years, mean (SD)</td><td align="char">70.5 (7.3)</td></tr><tr><td style="padding-left:10%" align="left">Education, years, mean (SD)</td><td align="char">14.3 (2.4)</td></tr><tr><td style="padding-left:10%" align="left">BMI, kg/m2, mean (SD)</td><td align="char">30.3 (6.4)</td></tr><tr><td style="padding-left:10%" align="left">Systolic blood pressure, mmHg, mean (SD)</td><td align="char">134.2 (17.9)</td></tr><tr><td style="padding-left:10%" align="left">Antihypertensive medication use, n (%)</td><td align="char">46 (51.7)</td></tr><tr><td style="padding-left:10%" align="left">Diabetes mellitus, n (%)</td><td align="char">24 (27.0)</td></tr><tr><td style="padding-left:10%" align="left">Current smoking, n (%)</td><td align="char">22 (24.7)</td></tr><tr><td align="left">Leptin markers</td><td align="char"/></tr><tr><td style="padding-left:10%" align="left">Leptin, NPX, mean (SD)</td><td align="char">−0.2 (1.4)</td></tr><tr><td style="padding-left:10%" align="left">Leptin receptor, NPX, mean (SD)</td><td align="char">0.1 (0.3)</td></tr><tr><td align="left">Neuropsychological test scores</td><td align="char"/></tr><tr><td style="padding-left:10%" align="left">TMT part A, min, median (IQR)</td><td align="char">0.57 (0.43, 0.70)</td></tr><tr><td style="padding-left:10%" align="left">TMT part B, min, median (IQR)</td><td align="char">1.49 (1.21, 2.29)</td></tr><tr><td style="padding-left:10%" align="left">Craft Story 21 Recall (Delayed), mean (SD)</td><td align="char">17.2 (6.5)</td></tr><tr><td align="left">MRI measures</td><td align="char"/></tr><tr><td style="padding-left:10%" align="left">Total cranial volume, cm3, mean (SD)</td><td align="char">1349.8 (142.0)</td></tr><tr><td style="padding-left:10%" align="left">Total brain volume, cm3, mean (SD)</td><td align="char">1049.2 (109.7)</td></tr><tr><td style="padding-left:10%" align="left">Total gray matter volume, cm3, mean (SD)</td><td align="char">582.8 (54.2)</td></tr><tr><td style="padding-left:10%" align="left">WMH volume, cm3, median (IQR)</td><td align="char">1.91 (0.87, 3.22)</td></tr><tr><td style="padding-left:10%" align="left">Fractional anisotropy, mean (SD)</td><td align="char">0.50 (0.01)</td></tr><tr><td style="padding-left:10%" align="left">Free water, median (IQR)</td><td align="char">0.18 (0.17, 0.21)</td></tr><tr><td style="padding-left:10%" align="left">PSMD × 10−4, median (IQR)</td><td align="char">3.25 (2.94, 3.49)</td></tr></tbody></table></div>Abbreviations: BMI, body mass index; IQR, interquartile range; MRI, magnetic resonance imaging; NPX, Normalized Protein eXpression; PSMD, peak width of skeletonized mean diffusivity; SD, standard deviation; TMT, Trail Making Test.; WMH, white matter hyperintensity.John Wiley &amp; Sons, Ltd.</transformed-table></extracted-table><extracted-table><table-id>alz13879-tbl-0005</table-id><table-label>TABLE 5</table-label><table-caption>Associations of leptin markers with MRI and cognitive outcomes in different sex subgroups.</table-caption><table-wrap-foot>Note: Values represent beta coefficients (β), and their corresponding standard errors (SE) and p‐values (p). Statistically significant findings at p ≤0.05 are indicated in bold.Abbreviations: FLI, free leptin index; HVOT, Hooper Visual Organization Test; MRI, magnetic resonance imaging; sOB‐R, soluble leptin receptor.aLinear regression models with the respective MRI marker or neuropsychological test score as the outcome and the respective leptin marker, sex, as well as their product term as the main predictors. Values represent the p‐value of the respective product term (p for interaction). Only significant findings at p ≤0.1 are presented.bLinear regression models with the respective MRI marker or neuropsychological test score as the outcome and the respective leptin marker as the main predictor, conducted by sex subgroups.cModels are adjusted for age, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and MRI acquisition.das percentage of total cranial volume.eThese variables have been natural log‐transformed to normalize their distributions.fModels are adjusted for age, education, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and neuropsychological assessment.gScores were multiplied by ‐1 so that higher scores reflect better cognitive performance.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="alz13879-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Associations of leptin markers with MRI and cognitive outcomes in different sex subgroups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Men<xref rid="alz13879-tbl5-note-0003" ref-type="table-fn"><sup>b</sup></xref></th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Women<xref rid="alz13879-tbl5-note-0003" ref-type="table-fn"><sup>b</sup></xref></th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Leptin marker</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic> for interaction<xref rid="alz13879-tbl5-note-0002" ref-type="table-fn"><sup>a</sup></xref></th><th align="char" rowspan="1" colspan="1"><italic toggle="yes">β</italic></th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">β</italic></th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MRI outcomes<xref rid="alz13879-tbl5-note-0004" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1"><italic toggle="yes">n</italic> = 958</td><td colspan="3" align="left" rowspan="1"><italic toggle="yes">n</italic> = 1070</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Total brain volume<xref rid="alz13879-tbl5-note-0005" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" rowspan="1" colspan="1">Leptin<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn"><sup>e</sup></xref></td><td align="char" rowspan="1" colspan="1">0.05</td><td align="char" rowspan="1" colspan="1">0.066</td><td align="char" rowspan="1" colspan="1">0.042</td><td align="char" rowspan="1" colspan="1">0.11</td><td align="char" rowspan="1" colspan="1">−0.045</td><td align="char" rowspan="1" colspan="1">0.040</td><td align="char" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Cognitive outcome<xref rid="alz13879-tbl5-note-0007" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1"><italic toggle="yes">n</italic> = 1076</td><td colspan="3" align="left" rowspan="1"><italic toggle="yes">n</italic> = 1186</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">HVOT<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" rowspan="1" colspan="1">Leptin<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn"><sup>e</sup></xref></td><td align="char" rowspan="1" colspan="1">0.04</td><td align="char" rowspan="1" colspan="1"><bold>0.112</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.047</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.02</bold></td><td align="char" rowspan="1" colspan="1">−0.016</td><td align="char" rowspan="1" colspan="1">0.040</td><td align="char" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">sOB‐R<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn"><sup>e</sup></xref></td><td align="char" rowspan="1" colspan="1">0.04</td><td align="char" rowspan="1" colspan="1">−0.058</td><td align="char" rowspan="1" colspan="1">0.034</td><td align="char" rowspan="1" colspan="1">0.09</td><td align="char" rowspan="1" colspan="1">0.032</td><td align="char" rowspan="1" colspan="1">0.028</td><td align="char" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">FLI<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn"><sup>e</sup></xref></td><td align="char" rowspan="1" colspan="1">0.007</td><td align="char" rowspan="1" colspan="1"><bold>0.123</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.044</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.006</bold></td><td align="char" rowspan="1" colspan="1">−0.036</td><td align="char" rowspan="1" colspan="1">0.038</td><td align="char" rowspan="1" colspan="1">0.35</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">TMT part B<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn"><sup>e</sup></xref>, <xref rid="alz13879-tbl5-note-0008" ref-type="table-fn"><sup>g</sup></xref></td><td align="left" rowspan="1" colspan="1">FLI<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn"><sup>e</sup></xref></td><td align="char" rowspan="1" colspan="1">0.1</td><td align="char" rowspan="1" colspan="1"><bold>0.092</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.044</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.04</bold></td><td align="char" rowspan="1" colspan="1">−0.004</td><td align="char" rowspan="1" colspan="1">0.038</td><td align="char" rowspan="1" colspan="1">0.93</td></tr></tbody></table><table-wrap-foot><fn id="alz13879-tbl5-note-0001"><p><italic toggle="yes">Note</italic>: Values represent beta coefficients (<italic toggle="yes">β</italic>), and their corresponding standard errors (SE) and <italic toggle="yes">p</italic>‐values (<italic toggle="yes">p</italic>). Statistically significant findings at <italic toggle="yes">p</italic> ≤0.05 are indicated in bold.</p></fn><fn id="alz13879-tbl5-note-0009"><p>Abbreviations: FLI, free leptin index; HVOT, Hooper Visual Organization Test; MRI, magnetic resonance imaging; sOB‐R, soluble leptin receptor.</p></fn><fn id="alz13879-tbl5-note-0002"><label><sup>a</sup></label><p>Linear regression models with the respective MRI marker or neuropsychological test score as the outcome and the respective leptin marker, sex, as well as their product term as the main predictors. Values represent the <italic toggle="yes">p</italic>‐value of the respective product term (<italic toggle="yes">p</italic> for interaction). Only significant findings at <italic toggle="yes">p</italic> ≤0.1 are presented.</p></fn><fn id="alz13879-tbl5-note-0003"><label><sup>b</sup></label><p>Linear regression models with the respective MRI marker or neuropsychological test score as the outcome and the respective leptin marker as the main predictor, conducted by sex subgroups.</p></fn><fn id="alz13879-tbl5-note-0004"><label><sup>c</sup></label><p>Models are adjusted for age, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and MRI acquisition.</p></fn><fn id="alz13879-tbl5-note-0005"><label><sup>d</sup></label><p>as percentage of total cranial volume.</p></fn><fn id="alz13879-tbl5-note-0006"><label><sup>e</sup></label><p>These variables have been natural log‐transformed to normalize their distributions.</p></fn><fn id="alz13879-tbl5-note-0007"><label><sup>f</sup></label><p>Models are adjusted for age, education, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and neuropsychological assessment.</p></fn><fn id="alz13879-tbl5-note-0008"><label><sup>g</sup></label><p>Scores were multiplied by ‐1 so that higher scores reflect better cognitive performance.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></original-table><transformed-table>TABLE 5<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Associations of leptin markers with MRI and cognitive outcomes in different sex subgroups.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><thead><tr><th align="left"/><th align="left"/><th align="left"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left">Men???</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left">Women???</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left">Parameter</th><th align="left">Leptin marker</th><th align="left">p for interaction???</th><th align="char">β</th><th align="left">SE</th><th align="left">p‐value</th><th align="left">β</th><th align="left">SE</th><th align="left">p‐value</th></tr></thead><tbody><tr><td align="left">MRI outcomes???</td><td align="left"/><td align="left"/><td colspan="3" align="left">n = 958</td><td colspan="3" align="left">n = 1070</td></tr><tr><td style="padding-left:10%" align="left">Total brain volume???</td><td align="left">Leptin???</td><td align="char">0.05</td><td align="char">0.066</td><td align="char">0.042</td><td align="char">0.11</td><td align="char">−0.045</td><td align="char">0.040</td><td align="char">0.26</td></tr><tr><td align="left">Cognitive outcome???</td><td align="left"/><td align="left"/><td colspan="3" align="left">n = 1076</td><td colspan="3" align="left">n = 1186</td></tr><tr><td style="padding-left:10%" align="left">HVOT???</td><td align="left">Leptin???</td><td align="char">0.04</td><td align="char">0.112</td><td align="char">0.047</td><td align="char">0.02</td><td align="char">−0.016</td><td align="char">0.040</td><td align="char">0.70</td></tr><tr><td align="left"/><td align="left">sOB‐R???</td><td align="char">0.04</td><td align="char">−0.058</td><td align="char">0.034</td><td align="char">0.09</td><td align="char">0.032</td><td align="char">0.028</td><td align="char">0.26</td></tr><tr><td align="left"/><td align="left">FLI???</td><td align="char">0.007</td><td align="char">0.123</td><td align="char">0.044</td><td align="char">0.006</td><td align="char">−0.036</td><td align="char">0.038</td><td align="char">0.35</td></tr><tr><td style="padding-left:10%" align="left">TMT part B???, ???</td><td align="left">FLI???</td><td align="char">0.1</td><td align="char">0.092</td><td align="char">0.044</td><td align="char">0.04</td><td align="char">−0.004</td><td align="char">0.038</td><td align="char">0.93</td></tr></tbody></table></div>Note: Values represent beta coefficients (β), and their corresponding standard errors (SE) and p‐values (p). Statistically significant findings at p ≤0.05 are indicated in bold.Abbreviations: FLI, free leptin index; HVOT, Hooper Visual Organization Test; MRI, magnetic resonance imaging; sOB‐R, soluble leptin receptor.aLinear regression models with the respective MRI marker or neuropsychological test score as the outcome and the respective leptin marker, sex, as well as their product term as the main predictors. Values represent the p‐value of the respective product term (p for interaction). Only significant findings at p ≤0.1 are presented.bLinear regression models with the respective MRI marker or neuropsychological test score as the outcome and the respective leptin marker as the main predictor, conducted by sex subgroups.cModels are adjusted for age, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and MRI acquisition.das percentage of total cranial volume.eThese variables have been natural log‐transformed to normalize their distributions.fModels are adjusted for age, education, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and neuropsychological assessment.gScores were multiplied by ‐1 so that higher scores reflect better cognitive performance.John Wiley &amp; Sons, Ltd.</transformed-table></extracted-table><extracted-table><table-id>alz13879-tbl-0006</table-id><table-label>TABLE 6</table-label><table-caption>Associations of leptin markers with MRI and cognitive outcomes in different WHR subgroups.</table-caption><table-wrap-foot>Note: Values represent beta coefficients (β), and their corresponding standard errors (SE) and p‐values (p). Statistically significant findings at p ≤0.05 are indicated in bold.Abbreviations: FLI, free leptin index; HVOT, Hooper Visual Organization Test; MRI, magnetic resonance imaging; sOB‐R, soluble leptin receptor; WHR, waist‐to‐hip ratio; WMH, white matter hyperintensity volume.aLinear regression models with the respective MRI measure or neuropsychological test score as the outcome and the respective leptin marker, WHR, as well as their product term as the main predictors. Values represent the p‐value of the respective product term (p for interaction). Only significant findings at p ≤ 0.1 are presented.bLinear regression models with the respective MRI measure or neuropsychological test score as the outcome and the respective leptin marker as the main predictor, conducted in different WHR subgroups.cModels are adjusted for age, sex, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and MRI acquisition.dThese variables have been natural log‐transformed to normalize their distributions.eModels are further adjusted for total cranial volume.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="alz13879-tbl-0006" content-type="TABLE" orientation="portrait"><label>TABLE 6</label><caption><p>Associations of leptin markers with MRI and cognitive outcomes in different WHR subgroups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">WHR Q<sub>1</sub>‐Q<sub>3</sub><xref rid="alz13879-tbl6-note-0003" ref-type="table-fn"><sup>b</sup></xref></th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">WHR Q<sub>4</sub><xref rid="alz13879-tbl6-note-0003" ref-type="table-fn"><sup>b</sup></xref></th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Leptin marker</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic> for interaction<xref rid="alz13879-tbl6-note-0002" ref-type="table-fn"><sup>a</sup></xref></th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">β</italic></th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">β</italic></th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MRI outcomes<xref rid="alz13879-tbl6-note-0004" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1"><italic toggle="yes">n</italic> = 1543</td><td colspan="3" align="left" rowspan="1"><italic toggle="yes">n</italic> = 483</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">PSMD<xref rid="alz13879-tbl6-note-0005" ref-type="table-fn"><sup>d</sup></xref>, <xref rid="alz13879-tbl6-note-0006" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" rowspan="1" colspan="1">sOB‐R<xref rid="alz13879-tbl6-note-0005" ref-type="table-fn"><sup>d</sup></xref></td><td align="char" rowspan="1" colspan="1">0.04</td><td align="char" rowspan="1" colspan="1"><bold>0.054</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.023</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.02</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.156</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.048</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">FLI<xref rid="alz13879-tbl6-note-0005" ref-type="table-fn"><sup>d</sup></xref></td><td align="char" rowspan="1" colspan="1">0.06</td><td align="char" rowspan="1" colspan="1">−0.059</td><td align="char" rowspan="1" colspan="1">0.031</td><td align="char" rowspan="1" colspan="1">0.06</td><td align="char" rowspan="1" colspan="1"><bold>−0.188</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.068</bold></td><td align="char" rowspan="1" colspan="1"><bold>0.006</bold></td></tr></tbody></table><table-wrap-foot><fn id="alz13879-tbl6-note-0001"><p><italic toggle="yes">Note</italic>: Values represent beta coefficients (<italic toggle="yes">β</italic>), and their corresponding standard errors (SE) and <italic toggle="yes">p</italic>‐values (<italic toggle="yes">p</italic>). Statistically significant findings at <italic toggle="yes">p</italic> ≤0.05 are indicated in bold.</p></fn><fn id="alz13879-tbl6-note-0007"><p>Abbreviations: FLI, free leptin index; HVOT, Hooper Visual Organization Test; MRI, magnetic resonance imaging; sOB‐R, soluble leptin receptor; WHR, waist‐to‐hip ratio; WMH, white matter hyperintensity volume.</p></fn><fn id="alz13879-tbl6-note-0002"><label><sup>a</sup></label><p>Linear regression models with the respective MRI measure or neuropsychological test score as the outcome and the respective leptin marker, WHR, as well as their product term as the main predictors. Values represent the <italic toggle="yes">p</italic>‐value of the respective product term (<italic toggle="yes">p</italic> for interaction). Only significant findings at <italic toggle="yes">p</italic> ≤ 0.1 are presented.</p></fn><fn id="alz13879-tbl6-note-0003"><label><sup>b</sup></label><p>Linear regression models with the respective MRI measure or neuropsychological test score as the outcome and the respective leptin marker as the main predictor, conducted in different WHR subgroups.</p></fn><fn id="alz13879-tbl6-note-0004"><p><sup>c</sup>Models are adjusted for age, sex, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and MRI acquisition.</p></fn><fn id="alz13879-tbl6-note-0005"><label><sup>d</sup></label><p>These variables have been natural log‐transformed to normalize their distributions.</p></fn><fn id="alz13879-tbl6-note-0006"><label><sup>e</sup></label><p>Models are further adjusted for total cranial volume.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></original-table><transformed-table>TABLE 6<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Associations of leptin markers with MRI and cognitive outcomes in different WHR subgroups.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><thead><tr><th align="left"/><th align="left"/><th align="left"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left">WHR Q1‐Q3???</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left">WHR Q4???</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left">Parameter</th><th align="left">Leptin marker</th><th align="left">p for interaction???</th><th align="left">β</th><th align="left">SE</th><th align="left">p‐value</th><th align="left">β</th><th align="left">SE</th><th align="left">p‐value</th></tr></thead><tbody><tr><td align="left">MRI outcomes???</td><td align="left"/><td align="left"/><td colspan="3" align="left">n = 1543</td><td colspan="3" align="left">n = 483</td></tr><tr><td style="padding-left:10%" align="left">PSMD???, ???</td><td align="left">sOB‐R???</td><td align="char">0.04</td><td align="char">0.054</td><td align="char">0.023</td><td align="char">0.02</td><td align="char">0.156</td><td align="char">0.048</td><td align="char">0.001</td></tr><tr><td align="left"/><td align="left">FLI???</td><td align="char">0.06</td><td align="char">−0.059</td><td align="char">0.031</td><td align="char">0.06</td><td align="char">−0.188</td><td align="char">0.068</td><td align="char">0.006</td></tr></tbody></table></div>Note: Values represent beta coefficients (β), and their corresponding standard errors (SE) and p‐values (p). Statistically significant findings at p ≤0.05 are indicated in bold.Abbreviations: FLI, free leptin index; HVOT, Hooper Visual Organization Test; MRI, magnetic resonance imaging; sOB‐R, soluble leptin receptor; WHR, waist‐to‐hip ratio; WMH, white matter hyperintensity volume.aLinear regression models with the respective MRI measure or neuropsychological test score as the outcome and the respective leptin marker, WHR, as well as their product term as the main predictors. Values represent the p‐value of the respective product term (p for interaction). Only significant findings at p ≤ 0.1 are presented.bLinear regression models with the respective MRI measure or neuropsychological test score as the outcome and the respective leptin marker as the main predictor, conducted in different WHR subgroups.cModels are adjusted for age, sex, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and MRI acquisition.dThese variables have been natural log‐transformed to normalize their distributions.eModels are further adjusted for total cranial volume.John Wiley &amp; Sons, Ltd.</transformed-table></extracted-table></extracted-tables-set>